Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) Profit After Tax (2016 - 2026)

Champions Oncology has reported Profit After Tax over the past 17 years, most recently at -$279000.0 for Q1 2026.

  • For Q1 2026, Profit After Tax fell 106.21% year-over-year to -$279000.0; the TTM value through Jan 2026 reached -$2.3 million, down 135.99%, while the annual FY2025 figure was $4.7 million, 164.6% up from the prior year.
  • Profit After Tax for Q1 2026 was -$279000.0 at Champions Oncology, down from $268000.0 in the prior quarter.
  • Over five years, Profit After Tax peaked at $4.5 million in Q1 2025 and troughed at -$2.6 million in Q3 2023.
  • A 5-year average of -$467352.9 and a median of -$319000.0 in 2022 define the central range for Profit After Tax.
  • Biggest five-year swings in Profit After Tax: crashed 12843.75% in 2023 and later skyrocketed 277.67% in 2025.
  • Year by year, Profit After Tax stood at -$16000.0 in 2022, then crashed by 12843.75% to -$2.1 million in 2023, then surged by 135.15% to $728000.0 in 2024, then tumbled by 63.19% to $268000.0 in 2025, then crashed by 204.1% to -$279000.0 in 2026.
  • Business Quant data shows Profit After Tax for CSBR at -$279000.0 in Q1 2026, $268000.0 in Q4 2025, and -$466000.0 in Q3 2025.